To check if Inj Pegylated Erythropoietin, in low doses, reduces need of transfusion without causing much side effects and without disease effect on cancer outcome.
Phase 2
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2021/08/035965
- Lead Sponsor
- Department of Medical Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a)Age >18 years.
b)Patients newly diagnosed with early breast cancer not on any chemotherapy or with 8 weeks or more of treatment remaining.
c)Corrected underlying Iron or Vitamin B12 deficiency.
d)Hemoglobin <= 10g/dL.
Exclusion Criteria
a)Patients with history of DVT, PE or IHD history.
b)Patients with performance status of ECOG 3 or more.
c)Pregnant or breast-feeding women.
d)Concomitant endocrine therapy.
e)Uncontrolled hypertension.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method